ZCCHC17

Across TCGA pan-cancer cohorts, ZCCHC17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZCCHC17 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZCCHC17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZCCHC17 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where ZCCHC17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.671	0.914	.001	40	view →
CCRCC	DFS	Quartile	II,III,IV	0.757	1.000	.008	7	view →
PDAC	DFS	Median	IV	0.934	0.238	.017	7	view →
LUAD	OS	Tertile	All	0.626	1.000	.002	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZCCHC17–HNSC (DFS)

Open the HNSC breakdown →